{ "schemaVersion": "2.1", "datasetVersion": "2026-09-11.1", "generatedAt": "2026-09-11", "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.", "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.", "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.", "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.", "changeLogPath": "/corrections#correction-ledger", "contactPath": "/corrections", "dataset": "peptide-evidence-checker-record", "canonicalPath": "/peptides/liraglutide", "canonicalUrl": "https://thepeptidefield.com/peptides/liraglutide", "record": { "slug": "liraglutide", "name": "Liraglutide", "aliases": [ "Victoza", "Saxenda", "GLP-1 analogue" ], "className": "GLP-1 receptor agonist", "family": "Metabolic peptide medicines", "sequenceLabel": "31 amino acids · acylated GLP-1 analogue", "tier": "Established", "evidenceContext": "Approved human outcomes", "statusLine": "FDA-approved products exist for specific indications", "productContext": "The ingredient name alone does not tell you which approved product the evidence covers. Liraglutide is an active ingredient. Victoza and Saxenda are distinct approved products with different labeled indications and product-specific prescribing information.", "approvedProducts": [ "Victoza", "Saxenda" ], "productRecords": [ { "name": "Victoza", "formulation": "Injection", "route": "Subcutaneous", "indicationScope": "Type 2 diabetes uses and labeled populations defined in the current product prescribing information.", "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022341Orig1s043lbl.pdf", "labelRevision": "November 2024" }, { "name": "Saxenda", "formulation": "Injection", "route": "Subcutaneous", "indicationScope": "Chronic weight management in the adult and pediatric populations defined in the current label.", "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf", "labelRevision": "February 2026" } ], "indications": [ "Type 2 diabetes for labeled populations", "Chronic weight management for labeled populations" ], "profile": { "humanOutcomes": { "level": "Strong", "note": "Large randomized programs support defined glycemic, cardiovascular, and weight-management outcomes." }, "humanPharmacology": { "level": "Strong", "note": "Approved labels characterize product-specific exposure, pharmacodynamics, and interactions." }, "safetyKnowledge": { "level": "Strong", "note": "Current labels describe contraindications, warnings, adverse reactions, and monitoring." }, "productCertainty": { "level": "Strong", "note": "High for authentic approved products; evidence does not transfer automatically to unapproved versions." } }, "oneLine": "An established prescription medicine. Its evidence applies to specific products, uses, groups of people, and current labels.", "reviewedAt": "July 23, 2026", "reviewedAtISO": "2026-07-23", "reviewHistory": [ { "date": "2026-07-23", "note": "Initial brief based on the current Saxenda label, LEADER, and FDA product records." } ], "whatItIs": "Liraglutide is an ingredient used in prescription medicines. GLP-1 is a body signal that helps control blood sugar and appetite. The ingredient name alone does not identify the product, use, form, or labeled group of people.", "whatWeKnow": "Studies and FDA-reviewed labels support specific outcomes. LEADER studied heart and blood-vessel outcomes in adults with type 2 diabetes at high cardiovascular risk. Saxenda has a separate chronic weight-management label.", "whatWeDoNotKnow": "These results do not show the same benefit for every person. They do not establish an anti-aging effect or show that approved products are equivalent to compounded, counterfeit, or research-labeled material.", "antiDoping": null, "safetyBoundary": "The current label has important reasons a product may not be appropriate, plus warnings and precautions. This guide does not determine eligibility or provide dose, titration, or product-switching instructions.", "relatedSlugs": [ "semaglutide", "tirzepatide", "retatrutide" ], "claims": [ { "claim": "“Liraglutide has established human outcome evidence.”", "verdict": "Supported with scope", "explanation": "Yes, for defined products, populations, indications, comparators, endpoints, and durations studied in major trials and reviewed labels.", "category": "Clinical outcomes", "evidenceBasis": "Randomized human outcomes", "scope": "Approved liraglutide products used in the populations and indications studied.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/27295427/", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf" ] }, { "claim": "“Every product sold as liraglutide is clinically equivalent.”", "verdict": "Misleading", "explanation": "Approved-product evidence includes product quality and labeling that cannot be assumed for every compounded or unapproved item.", "category": "Product equivalence", "evidenceBasis": "Regulatory or product record", "scope": "Product identity, formulation, quality, and labeling all matter.", "sourceUrls": [ "https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases" ] }, { "claim": "“Cardiovascular trial results prove a universal longevity benefit.”", "verdict": "Not established", "explanation": "LEADER tested a defined cardiovascular composite in a high-risk type 2 diabetes population, not lifespan extension in the general population.", "category": "Longevity", "evidenceBasis": "Randomized human outcomes", "scope": "Adults with type 2 diabetes and high cardiovascular risk in LEADER.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/27295427/" ] } ], "sources": [ { "label": "VICTOZA (liraglutide) prescribing information", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022341Orig1s043lbl.pdf", "kind": "Drug label", "year": 2024, "accessedAt": "2026-07-23" }, { "label": "SAXENDA (liraglutide) prescribing information", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf", "kind": "Drug label", "year": 2026, "accessedAt": "2026-07-23" }, { "label": "Liraglutide and cardiovascular outcomes in type 2 diabetes", "publisher": "PubMed · New England Journal of Medicine", "url": "https://pubmed.ncbi.nlm.nih.gov/27295427/", "kind": "Randomized trial", "year": 2016, "accessedAt": "2026-07-23" }, { "label": "Drug approvals and databases", "publisher": "U.S. Food and Drug Administration", "url": "https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases", "kind": "Regulatory", "year": 2026, "accessedAt": "2026-07-23" } ], "antiDopingReview": { "status": "Not assessed", "detail": "This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.", "sourceUrl": null, "reviewedAtISO": "2026-07-23" } } }